Introduction
============

Chronic kidney disease (CKD) is a growing health burden worldwide, as well as in Korea \[[@ref1]\]. The numbers of patients with CKD and end-stage renal disease (ESRD) are increasing rapidly \[[@ref2],[@ref3]\]. Not only CKD is a significant factor in morbidity and mortality, but the medical expenses for management of CKD are increasing remarkably.

In order to broaden knowledge regarding the risk factors for CKD progression and adverse outcomes, the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) was established with the support of the Korea Center for Disease Control and Prevention (KCDC) \[[@ref4]\]. The study protocol was approved by the ethical committee at each participating center ([Supplementary materials](#S1){ref-type="supplementary-material"}, available online). From 2011 until 2016, the KNOW-CKD recruited 2,238 adult patients with CKD from stage G1 to G5 who were not receiving renal replacement therapy from nine tertiary care hospitals throughout Korea \[[@ref5]\]. All the subjects being ethnic Koreans, the KNOW-CKD is expected to provide high-level evidence from Koreans on the clinical courses and clinical and biological factors for CKD progression and/or adverse outcomes, and diverse deficits related to CKD such as cardiovascular comorbidity, anemia, mineral metabolic derangements, quality of life (QOL), and health habits. Unlike other CKD cohort studies such as the Chronic Renal Insufficiency Cohort (CRIC) of the United States \[[@ref6],[@ref7]\] or the Chronic Kidney Disease Japan Cohort (CKD-JAC) of Japan \[[@ref8]\], the KNOW-CKD study includes CKD at early stages (stages G1 and G2) as well as advanced stages, providing a platform on which to investigate the courses of early CKD over the long term.

As of December 2019, the KNOW-CKD has published over 50 articles in international peer-reviewed journals. The present article provides the basic design and summary of the major findings from the KNOW-CKD study.

Study design, recruitment, and follow-up status
===============================================

Details of the rationale and design of the KNOW-CKD study have been described previously \[[@ref4]\]. Briefly, for Phase I of the KNOW-CKD study, 2,238 subjects with CKD were recruited from nine university-affiliated tertiary-care hospitals throughout Korea from 2011 until 2016. Nephrologists, epidemiologists, specialists in laboratory medicine, and biostatisticians have participated in this study. The study is funded and supervised by the KCDC. The protocol summary is also registered at the ClinicalTrials.gov with accession number NCT01630486. The participants were all ethnic Koreans, aged between 20 and 75 years, with CKD stages from G1 to G5 (pre-dialysis). CKD stages were defined on the basis of the estimated glomerular filtration rate (eGFR) calculated using the CKD Epidemiology Collaboration (CKD-EPI) (cr) formula \[[@ref9]\]. The serum creatinine was measured at a central laboratory (LabGenomics, Seongnam, Korea), using an assay traceable to the international reference material.

All enrolled subjects were categorized into the following subgroups: glomerular diseases (GN), diabetic nephropathy (DN), hypertensive nephropathy (HTN), polycystic kidney disease (PKD), and unclassified, based on the etiology of CKD. HTN and PKD were oversampled in order to compare the four major causative diseases of CKD. The clinical information and laboratory tests performed at each study visit are depicted in [Table 1](#T1){ref-type="table"} \[[@ref5]\].

Composite renal events were defined as doubling of serum creatinine, eGFR halving, or development of ESRD. ESRD was defined as starting maintenance dialysis for more than three months or receiving kidney transplantation. CV events were defined as any first event of the following: acute myocardial infarction, unstable angina, ischemic or hemorrhagic cerebral stroke, congestive heart failure, symptomatic arrhythmia, aggravated valvular heart disease, pericardial disease, abdominal aortic aneurysm, and severe peripheral arterial disease that required hospitalization, interventions, or therapy during follow-up. Data on the time and specific causes of mortality were obtained either from hospital records or from the Korean Statistical Information Service (KOSIS). Other events such as all-cause hospitalization, surgery, and fracture were also collected during the follow-up period. All the events described above were recorded on a special report form and further adjudicated by the Central Adjudication Committee of the KNOW-CKD study.

The baseline characteristics of the study subjects are described in [Table 2](#T2){ref-type="table"}.

As of March 31, 2019, among 2,238 subjects enrolled in the study, there were 107 deaths and 165 fatal or non-fatal CV events after 5.0-year (median) follow-up. Five hundred thirty three subjects developed ESRD ([Table 3](#T3){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}).

We subsequently summarize the major findings of the KNOW-CKD study in several areas: 1) socio-economics and health-related habits, 2) CV comorbidity, 3) anemia, 4) mineral bone disease, 5) nutrition and QOL, 6) biomarker discovery studies, 7) clinical courses and outcomes, and 8) international comparison.

Socio-economics and health-related habits
=========================================

Socio-economic status (SES), defined by educational attainment and income levels, contributes to a complex set of socio-economic determinants, including medical insurance, transportation, stress level, housing quality, and accessibility to medical care \[[@ref10]\]. Such determinants may interact and combine to affect health outcomes. Among the KNOW-CKD participants, lower SES was significantly associated with left ventricular hypertrophy, which is a major predictor of future CV outcomes \[[@ref11]\]. Currently, analysis of longitudinal follow-up data is underway and is expected to reveal whether lower SES is associated with the risk for CKD progression or poorer CV outcomes.

While increased body mass index (BMI) is a well-established CVD risk factor in the general population, it is paradoxically associated with survival benefits in CKD and ESRD patients \[[@ref12],[@ref13]\]. In contrast to BMI, anthropometric indices representing central obesity such as waist-to-hip ratio (WHR) and waist circumference (WC) are suggested to be directly associated with CVD and mortality. The KNOW-CKD subjects were categorized into 6 groups according to a combination of BMI (normal, overweight, obese) and WHR (lower or higher than sex-specific median WHR). Here, the normal BMI and higher WHR group had the highest risk of coronary artery calcification (CAC) compared with the normal BMI and lower WHR group (odds ratio, 2.104; 95% confidence interval \[CI\], 1.074-4.121). Thus, BMI and WHR-two predictors of obesity-can help to discriminate CVD risk in Korean CKD patients \[[@ref14]\].

The KNOW-CKD investigated the effects of health habits on CKD outcome. The study collected detailed information on exercise, alcohol drinking, and smoking through self-reported questionnaires. Compared with non-drinkers, regular and occasional binge drinkers had a 2.2-fold (95% CI, 1.38-3.46) and a 2.0-fold (95% CI, 1.33-2.98) higher risk of CKD progression, respectively. This association was particularly evident in patients who had decreased kidney function and proteinuria \[[@ref15]\].

Cardiovascular disease profile at study entry
=============================================

Since CKD is associated with heavy CVD burden, thorough CV evaluations including echocardiography, coronary computed tomography, and pulse wave velocity (PWV) measurements were conducted at study entry and regularly thereafter. The overall prevalence of comorbid CVD at study entry was 14.4% in all study participants and was the highest in the DN subgroup followed by the HTN subgroup. The DN subgroup had more adverse CV risk profiles (higher systolic blood pressure (BP) and higher levels of cardiac troponin T, left ventricular mass index, coronary calcium score, and brachial-ankle PWV) than the other subgroups. These CV risk profiles were all inversely correlated with eGFR \[[@ref16]\]. Metabolic acidosis defined as a serum bicarbonate level of \< 22 mmol/L was independently associated with arterial stiffness \[[@ref17]\]. Vigorous investigation to search for the risk factors and biomarkers related to CVD is under way.

Coronary artery calcification
=============================

CAC is a well‐known predictor of CV events and high mortality in the general population \[[@ref18]\] and in patients with CKD \[[@ref19],[@ref20]\]. The KNOW-CKD investigated the clinical and biochemical factors related to CAC. There was a gradual and independent association between low eGFR and CAC at the study entry in the KNOW-CKD subjects \[[@ref21]\]. In view of arterial stiffness measured by PWV, the subjects with higher baPWV (brachial-ankle PWV) exhibited higher prevalence of CAC, suggesting that increased arterial stiffness is independently associated with CAC \[[@ref22]\].

Anemia
======

Anemia is a well-known complication in CKD and is associated with the progression of CKD, poor QOL, and increase in morbidity and mortality. Overall prevalence of anemia in the KNOW-CKD cohort was 45.0%, and DN as a cause, advanced CKD stages, BMI, smoking, leukocyte count, serum albumin, iron markers, calcium, and phosphorus concentration were identified as independent risk factors for anemia \[[@ref23]\].

Recently, hepcidin was found to be a key molecule mediating iron metabolism and transport. Binding of hepcidin to ferroportin, an iron-exporting transcellular channel, induces the internalization and degradation of ferroportin and disturbs iron efflux from cells to plasma, ultimately lowering serum iron levels and sequestering iron in iron-storage sites \[[@ref24]\]. The KNOW-CKD showed from a large number of CKD patients that lower eGFR is associated with higher serum hepcidin levels, particularly in advanced CKD. Iron supplementation was positively correlated with serum hepcidin levels, especially in patients with early CKD. The higher hepcidin level in erythropoiesis-stimulating agents (ESA) users, as compared with non-users, suggests that hepcidin is a key peptide involved in ESA resistance, suggesting a possible role of hepcidin modulation in anemia treatment \[[@ref25]\]. Indices of iron profiles were analyzed in relation to anemia in CKD. Transferrin saturation and hepcidin were significantly associated with anemia status, whereas serum ferritin was not. Hepcidin was particularly associated with severe anemia in advanced CKD stages \[[@ref26]\], suggesting a possible role of hepcidin as a predictive marker of anemia in CKD.

Mineral bone disease of CKD
===========================

In KNOW-CKD study patients, serum vitamin D levels began to decline in the early stages of CKD before significant elevations in fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (iPTH). Moreover, FGF23 elevation was observed concurrently with increased iPTH with declining eGFR \[[@ref27]\], in contrast to Western populations. There is a stepwise decrease in serum Klotho concentration with the decline of eGFR \[[@ref28]\]. The prevalence of osteoporosis was higher in advanced CKD patients \[[@ref27]\]. Also, increased vascular calcification scores are noted in both early and advanced stages of CKD, similar to that of Western populations \[[@ref27]\].

In female patients with CKD, increased serum osteoprotegerin (OPG) levels were independently associated with decreased bone mineral density in the lumbar spine and total hip and with increased risk of osteoporosis. Therefore, measurement of serum OPG concentration may be useful as a predictor for determining bone loss in CKD patients \[[@ref29]\].

Moreover, there may be a crosslink between the markers of bone mineral metabolism and those of anemia. The KNOW-CKD showed that elevated serum phosphorus and iPTH are associated with an increase in hepcidin, while elevated vitamin D levels are associated with a decrease in serum hepcidin levels after adjustment \[[@ref30]\]. High FGF23 was associated with anemia at baseline and development of anemia during follow-up \[[@ref31]\], which is consistent with the observation from the CRIC cohort \[[@ref32]\]. Taken together, these findings suggest that correcting mineral metabolic derangement may be a possible therapeutic approach in treating anemia in CKD.

Nutrition and QOL in CKD
========================

Malnutrition or protein-energy wasting (PEW) in CKD is prevalent with decreasing renal function and is a strong indicator of adverse outcomes. Multiple mechanisms are involved in nutritional problems in CKD patients. Insufficient food intake caused by uremia-induced anorexia alone does not account for the unfavorable nutritional changes. There are additional contributing factors, such as chronic inflammation, acidosis, multiple hormonal disturbances, comorbidities, and physical inactivity \[[@ref33]\]. The prevalence of PEW in the KNOW-CKD study was about 9.0% \[[@ref34]\] according to the International Society of Renal Nutrition and Metabolism (ISRNM) criteria \[[@ref35]\] and tended to increase with advanced stage in pre-dialysis CKD. In the multivariate logistic regression model, PEW was independently associated with eGFR, total CO~2~, physical activity, diabetes, and high sensitivity C-reactive protein (hs-CRP) \[[@ref34]\].

Health-related quality of life (HRQOL) is a concept in QOL that focuses on the effects of illness, and specifically on the impact that treatment may have on QOL. It is generally accepted that HRQOL represents the positive and negative aspects of patients\' symptoms, including emotional, social, and cognitive functions, disease burden, and treatment side effects. Recently, HRQOL has been accepted as an important health outcome. Patients with advanced CKD have multiple, complex comorbid conditions that can produce poor HRQOL \[[@ref36]\]. The KNOW-CKD study acquires information on HRQOL, SES such as occupation, academic year, monthly income, sleep quality and quantity, and health-related habits through patient-reported questionnaires at the study entry and regularly thereafter. There was a significant association between serum vitamin D levels and kidney disease component summary (KDCS) and mental component summary (MCS) scores in pre-dialysis CKD patients \[[@ref37]\]. Sleep duration was also correlated with HRQOL in patients with CKD. Too long or short sleep durations were associated with poor HRQOL \[[@ref38]\]. WC is a better indicator of poor physical HRQOL than BMI. The association between WC and physical HRQOL is modified by age, sex, eGFR, and comorbidities such as diabetes and CVD \[[@ref39]\].

The second phase of the KNOW-CKD study (KNOW-CKD Phase II), which is scheduled to recruit 1,500 subjects between 2019 and 2021, will emphasize nutritional assessment and evaluation of QOL and cognitive function change. It is strongly anticipated that the KNOW-CKD Phase II will provide us with robust medical and clinical knowledge on the nutritional issues and QOL in CKD patients.

CKD progression
===============

The KNOW-CKD defined the renal end-point as either eGFR halving or ESRD occurrence. The composite renal event was defined as one of the two renal events above. General risk factors of renal composite end-point from the KNOW-CKD are depicted in [Table 4](#T4){ref-type="table"}. As a surrogate of renal progression, eGFR slope was calculated based on the mixed model.

Elucidating and modulating the major risk factors of CKD to delay progression are the key aims of the KNOW-CKD study. Regarding the association between obesity and CKD progression, there have been conflicting results. Here, we defined metabolic abnormality as the presence of three or more of the following five components: hypertension, fasting glucose level ≥ 126 mg/dL or the presence of type 2 diabetes, triglyceride level \> 150 mg/dL or use of lipid-lowering drugs, high-density lipoprotein cholesterol level ≤ 40 mg/dL in men and ≤ 50 mg/dL in women, and hs-CRP level \> 1 mg/L. Obesity was defined as BMI ≥ 25 kg/m^2^. The KNOW-CKD showed that both metabolic abnormalities and obesity are associated with a significantly increased risk for CKD progression. Notably, obese patients without metabolic abnormalities also have an elevated risk for CKD progression ([Fig. 2](#F2){ref-type="fig"}) \[[@ref40]\]. Another study investigated the effect of dietary salt intake on CKD progression using 24-hour urinary Na excretion as a proxy \[[@ref41]\]. Here, it was shown that, compared with the reference group (urinary Na excretion 104.2-145.1 mEq/day), the highest quartile group was associated with 1.8 times higher risk of composite renal outcome (urinary Na excretion ≥ 192.9 mEq/day, P = 0.015) in a multivariable hazards model ([Fig. 3](#F3){ref-type="fig"}) \[[@ref41]\]. Arterial stiffness measured by PWV was also shown to be a risk factor for renal outcome. High baPWV, if accompanied by a high heart-to-femoral PWV (hfPWV), was shown to be associated with rapid eGFR decline, suggesting that central and peripheral PWVs may simultaneously affect rapid eGFR decline \[[@ref42]\].

Dietary protein restriction may be beneficial to CKD patients by delaying CKD progression. However, it may be harmful to patients at risk of PEW. Therefore, dietary protein restriction may be a double-edged sword for CKD patients. The KNOW-CKD analyzed associations between dietary protein intake (DPI) assessed by 24-hour urine nitrogen excretion \[[@ref43]\], PEW, and renal outcome. Low DPI was found to be associated with PEW, which may attenuate the potential benefits of a low-protein diet on CKD progression. Therefore, caution about the risk of PEW particularly needs to be expressed to patients \[[@ref44]\].

To date, several biochemical markers shown to be independently associated with CKD progression by the KNOW-CKD study are hyperuricemia \[[@ref45]\], low urine osmolality \[[@ref46]\], low urine chloride \[[@ref47]\], and low urine potassium \[[@ref48]\] levels.

CV outcome and death in KNOW-CKD
================================

As mentioned above, among 2,238 subjects, there were 107 deaths and 165 fatal or non-fatal CV events as of March 31, 2019. Compared with the incidences of renal end-points, the incidences of CV outcomes and death were relatively low, as shown in [Table 3](#T3){ref-type="table"}. Observational studies from Western CKD populations reported that patients with CKD have a higher risk of death than risk of progression to ESRD \[[@ref49]\]. However, in our Korean CKD population, incidences of any CV event (16.2 per 1,000 patient-years) or all-cause death (10.1 per 1,000 patient-years) were much lower than those of ESRD, which were 57 per 1,000 patient-years. This is similar to the report from Japanese CKD subjects \[[@ref50]\] and was also shown in a recent international collaborative study comparing the outcomes of various CKD cohorts \[[@ref51]\]. Investigation on the risk factors of adverse CV outcome or death will be conducted when a significant number of end-points is reached to ensure statistical power.

Biomarker discovery in CKD
==========================

Biomarkers are molecules that are objectively measured and evaluated as an indicator of normal biological process, pathologic process, or pharmacologic response. Recent advances in molecular biology, functional genomics, and proteomics have elucidated many candidate biomarkers in acute kidney injury and CKD, such as neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and liver-type fatty acid-binding protein. The KNOW-CKD has found several biomarker candidate molecules that can predict major adverse outcomes of CKD. Candidate biomarkers of CKD outcomes are cystatin C \[[@ref21]\], albuminuria \[[@ref52]\], adiponectin \[[@ref53]-[@ref58]\], FGF23 \[[@ref31],[@ref59]\], high density lipoprotein cholesterol \[[@ref60]\], troponin T \[[@ref61]\] ([Fig. 4](#F4){ref-type="fig"}), hepcidin \[[@ref26],[@ref30]\], Klotho \[[@ref28],[@ref62]\], OPG \[[@ref63]\], and various urinary markers \[[@ref46],[@ref47],[@ref64]-[@ref66]\]. The main results of the biomarker studies are described in [Table 5](#T5){ref-type="table"} \[[@ref28],[@ref53]-[@ref66]\].

International collaborations for CKD study
==========================================

The incidence, prevalence, and clinical outcomes of CKD/ESRD vary depending on country and ethnicity \[[@ref67],[@ref68]\]. The KNOW-CKD has been actively participating in the International Network of CKD Cohort Studies (iNET-CKD) \[[@ref69]\] in pursuit of the factors explaining such differences through inter-ethnic and international comparison and meta-analysis.

In one recent meta-analysis \[[@ref70]\], the iNET-CKD reported crude prevalence of uncontrolled BP among 17 cohort studies, including 34,602 individuals with eGFR \< 60 mL/min/1.73 m^2^ and treated hypertension adjusted for potential confounders. Crude prevalence of BP ≥ 140/90 mmHg ranged from 28% to 61%. Adjusted prevalence ratios indicated poorer hypertension control in cohorts from European countries, India, and Uruguay, and better control in North America and high-income Asian countries including Korea and Japan. Particularly, the KNOW-CKD exhibited the lowest prevalence of uncontrolled hypertension (27.3%) among the 17 participating CKD cohorts.

Another international meta-analysis study compared the longitudinal outcomes of CKD across eight iNET-CKD cohorts \[[@ref51]\]. The risks of CKD progression, ESRD, death, and CVD vary across countries even after adjusting for age, sex, comorbidities, and baseline laboratory results. The KNOW-CKD cohort population, as compared to the other seven cohorts in Europe, Japan, North America, and South America, exhibited relatively lower incidence of all-cause mortality, while exhibiting higher incidences of CKD progression and ESRD, after adjustment ([Fig. 5](#F5){ref-type="fig"}).

Taken together, the findings from the two international comparison studies above warrant a search for the specific genetic, socio-economic, and cultural factors in the Korean CKD population that explain this difference.

KNOW-CKD Phase II
=================

The KNOW-CKD has recently launched Phase II enrollment for 2019 through 2021 ([Table 6](#T6){ref-type="table"}). The aims of the KNOW-CKD Phase II study are as follows: 1) to enlarge the total pool of CKD patients in the cohort, particularly those with eGFR \< 60 mL/min/1.73 m^2^ and high risks of renal progression 2) to focus more on DN and HTN, and 3) to emphasize the health habits of the CKD patients by obtaining more information on dietary patterns, nutritional status, and cognitive functions. It is expected that the KNOW-CKD Phase II will not only reinforce the statistical power of the KNOW-CKD Phase I but also provide robust scientific evidence on the significance of health habits and dietary modification on the CKD outcomes.

Summary and conclusion
======================

As the nation's largest CKD cohort, the KNOW-CKD has relentlessly pursued answers to the basic questions on clinical courses and elucidation of the risk factors for adverse outcomes from the Korean CKD population. Particularly, among various aspects of CKD, greater emphases were placed upon socio-economics, nutrition and QOL, health habits, CKD progression, CV comorbidity and outcome, anemia, mineral bone disease, biomarker discovery, and international and inter-ethnic comparison. By following the subjects for more than 10 years, the KNOW-CKD will eventually offer a prediction model for the long-term consequences of CKD such as the occurrences of ESRD, CVD, and death, thereby enabling the identification and treatment of the at-risk population that requires extra medical attention.

The KNOW-CKD Investigator Group
===============================

**Patient Recruitment.** *Seoul National University Hospital*, Curie Ahn, MD, Kook-Hwan Oh, MD (PI), Hajeong Lee, MD, Seung Seok Han, MD, Hyunjin Ryu, MD, Eunjeong Kang, MD, Minjung Kang, MD, Youngok Ko, RN, Jeongok So, RN, and Aram Lee, RN. *Seoul National University Bundang Hospital*, Dong Wan Chae, MD (SubPI), Yong Jin Yi MD, Hyun Jin Cho, RN and Jung Eun Oh RN. Yonsei University, Severance Hospital, Kyu Hun Choi, MD (SubPI), Seung Hyeok Han, MD, Tae-Hyun Yoo, MD, and Mi Hyun Yu, RN. *Kangbuk Samsung Hospital*, Kyu-Beck Lee, MD and Young Youl Hyun, MD, Hyun Jung Kim, RN. *The Catholic University of Korea, Seoul St. Mary's Hospital*, Yong-Soo Kim, MD and Sol Ji Kim, RN. *Gachon University Gil Medical Center*, Wookyung Chung, MD, Ji Yong Jung, MD and Kwon Eun Jin, RN. *Nowon Eulji Medical Center, Eulji University*. Su Ah Sung, MD, Sung Woo Lee, MD, Hyang Ki Min, MD, and Soon Bin Kwon, RN. *Chonnam National University Hospital*, Soo Wan Kim, MD, Seong Kwon Ma, MD, Eun Hui Bae, MD, Chang Seong Kim, MD, Hong Sang Choi, MD, Minah Kim, MD, Tae Ryom Oh, MD, Sang Heon Suh, MD, Su Hyun Song, MD, and Se Jeong Lee, RN. *Inje University, Pusan Paik Hospital*, Yeong Hoon Kim, MD, Sun Woo Kang, MD, Hoseok Koo, MD, Tae Hee Kim, MD and Yun Mi Kim. MD and Young Eun Oh, MSc. *Pusan National University Hospital*, Eun Young Seong, MD, Sang Heon Song, MD, Miyeun Han, MD, Hyo Jin Kim, MD, Seunghee Ji, RN, *National Health Insurance Service Ilsan Hospital*, Tae Ik Chang, MD, Ea Wha Kang, MD, Kyoung Sook Park, MD, Aei Kyung Choi, RN. Hallym University Dongtan Sacred Heart Hospital Ja-Ryong Koo, MD, Jang-Won Seo, MD, Sun Ryoung Choi, MD, Seon Ha Baek, MD and Myung Sun Kim, RN. *Seoul National University Boramae Medical Center*, Yun Kyu Oh, MD (SubPI), Jeong Mi Park, RN.

**Epidemiology and Biostatistics.** Department of Preventive Medicine, Seoul National University College of Medicine, Byung-Joo Park, MD, Sue K. Park, MD, Choonghyun Ahn, MD and Kyungsik Kim, BSc. School of Medicine, Inha University Department of Prevention and Management, Inha University Hospital, Joongyub Lee, MD.

**Data Coordinating Center.** Medical Research Collaborating Center, *Seoul National University Hospital* and Seoul National University College of Medicine, Jayoun Kim, PhD, Dayeon Nam, RN, Soohee Kang, MSc, Juhee Lee, MSc, and Heejung Ahn, RN. **Central Laboratory.** Dong Hee Seo, MD, and Soyoung Kim, MD, LabGenomics, Korea. **Biobank.** Korea Biobank, Korea Centers for Disease Control and Prevention, Osong, Korea. **Korea Center for Disease Control and Prevention.** Ok Park, Il Yoel Kim, Sung Hyun Kang, and Kyoung Hwa Kim

Details on the design, patient enrollment, investigator group, research publications, and annual report are available at the website of the KNOW-CKD study (<http://www.know-ckd.org>).
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![Incidences of major outcomes of KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) and comparison with the Chronic Renal Insufficiency Cohort (CRIC) cohort.\
CRIC comprises CKD subjects with estimated glomerular filtration rate (eGFR) between 20 to 70 mL/min/1.73 m^2^. Therefore, it is more relevant to compare CRIC and KNOW-CKD at stages G3a-5, rather than total KNOW-CKD subjects.\
ESRD, end-stage renal disease.](KRCP-39-121-f1){#F1}

![Adjusted Kaplan-Meier curve for cumulative renal events according to metabolic subtypes \[[@ref40]\], reproduced with permission.\
*P* \< 0.001.\
MA, metabolic abnormality.](KRCP-39-121-f2){#F2}

![Association of measured 24-hour urinary sodium excretion with hazard ratio of chronic kidney disease progression in fully-adjusted model \[[@ref41]\].\
Note the relatively linear relationship between measured 24-hour urinary sodium excretion and risk of composite renal outcomes at the reference of urinary sodium excretion ≥ 120 mEq/day.](KRCP-39-121-f3){#F3}

![The association between high-sensitivity troponin T (hs-TnT) and longitudinal echocardiographic changes \[[@ref61]\].\
(A) Left ventricular hypertrophy: adjusted to age, sex, mean arterial pressure, diabetes mellitus (DM), hypertension (HTN), coronary artery disease, chronic kidney disease (CKD) stage, body mass index (BMI), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), hemoglobin. (B) Diastolic dysfunction: adjusted to age, sex, DM, HTN, CKD stage, BMI, HDL-C, TG, C-reactive protein, smoking history.](KRCP-39-121-f4){#F4}

![Adjusted incidence rates of all-cause death (A) and composite of estimated glomerular filtration rate (eGFR) halving or end-stage renal disease (ESRD) (B) across the International Network of Chronic Kidney Disease studies (iNET-CKD) \[[@ref51]\], reproduced with permission.\
Adjusted incidence rates were estimated through direct standardization using the total population from all study groups as the standard. Adjustments included age, sex, and eGFR at baseline. Individuals included were 18 years and older and had an eGFR assessment at baseline between 15 and 60 mL/min per 1.73 m^2^. Cochran's Q and I^2^ statistics were estimated to assess heterogeneity in incidence rates across iNET-CKD studies.\
AUS, Australia; CI, confidence interval; CAN, Canada; CAN-PREDDICT, Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events; CKD-JAC, Chronic Kidney Disease Japan Cohort; CKD-QLD, Chronic Kidney Disease in Queensland; CRIC, Chronic Renal Insufficiency Study; GBR, Great Britain; JPN, Japan; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; KOR, Republic of Korea; NRHP, National Renal Healthcare Program; RIISC, Renal Impairment in Secondary Care; URY, Uruguay; USA, United States of America.](KRCP-39-121-f5){#F5}

###### 

Sequence and schedule of KNOW-CKD study clinic visits and procedures

  Parameter                                                                                                                                                                                                                                                                Screen   At entry   6 mo   1 yr   2 yr   3 yr   4 yr   5 yr   6 yr   7 yr   8 yr   9 yr
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------- ---------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Informed consent                                                                                                                                                                                                                                                         ●                                                                                  
  Demographic information, Medical History                                                                                                                                                                                                                                 ●                                                                                  
  Recent events                                                                                                                                                                                                                                                                     ●          ●      ●      ●      ●      ●      ●      ●      ●      ●      ●
  Medications                                                                                                                                                                                                                                                              ●        ●          ●      ●      ●      ●      ●      ●      ●      ●      ●      ●
  HRQOL/Health related questionnaire                                                                                                                                                                                                                                       ●                   ●                                                              
  BP/anthropometry                                                                                                                                                                                                                                                         ●        ●          ●      ●      ●      ●      ●      ●      ●      ●      ●      ●
  CBC, chemistry, Cr[a](#t1fn2){ref-type="table-fn"}, eGFR, Cystatin C[a](#t1fn2){ref-type="table-fn"}, HbA1c                                                                                                                                                              ●        ●          ●      ●      ●      ●      ●      ●      ●      ●      ●      ●
  Lipid panel, CRP, iron panel                                                                                                                                                                                                                                             ●                   ●             ●                                                
  Intact PTH[a](#t1fn2){ref-type="table-fn"}, 25 D[a](#t1fn2){ref-type="table-fn"}, 1,25 D[a](#t1fn2){ref-type="table-fn"}, troponin T[a](#t1fn2){ref-type="table-fn"}                                                                                                     ●                   ●             ●                                                
  UA with microscopy                                                                                                                                                                                                                                                       ●                   ●             ●                                                
  24HU -- Na/K/Ca/P/Cr/Urea/Uric acid/protein, Spot urine electrolytes[a](#t1fn2){ref-type="table-fn"}, albumin[a](#t1fn2){ref-type="table-fn"}, protein[a](#t1fn2){ref-type="table-fn"}, osmolality[a](#t1fn2){ref-type="table-fn"}, Cr[a](#t1fn2){ref-type="table-fn"}   ●                   ●             ●                                                
  ECG, chest X ray                                                                                                                                                                                                                                                         ●                   ●             ●             ●                                  
  EchoCG, PWV, ABI, Coronary CT, LS spine lateral X-ray, DEXA BMD                                                                                                                                                                                                          ●                   ●                                                              
  Biosamples for DNA                                                                                                                                                                                                                                                       ●                                                                                  
  Serum/urine biosample                                                                                                                                                                                                                                                    ●        ●          ●      ●             ●             ●             ●             ●
  Fundus exam (DM subgroup)                                                                                                                                                                                                                                                ●                                                                                  
  Abdomen CT (PKD subgroup)                                                                                                                                                                                                                                                ●                   ●             ●             ●             ●             ●      
  Family screen (PKD subgroup)                                                                                                                                                                                                                                             ●                                                                                  

1,25 D, 1,25-dihydroxyvitamin D; 24HU, 24-hour urine; 25 D, 25-hydroxyvitamine D; ABI, ankle-brachial index; BP, blood pressure; CBC, complete blood count; Cr, creatinine; CRP, C-reactive protein; CT, computed tomography; DEXA BMD, dual energy x-ray absorptiometry bone mineral density; DM, diabetes mellitus; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HRQOL, health-related quality of life; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; LS, lumbosacral; PKD, polycystic kidney disease; PTH, parathyroid hormone; PWV, pulse wave velocity; UA, urinalysis.

Measured at the central laboratory.

###### 

Baseline demographic and clinical characteristics of KNOW-CKD subjects at study entry

  Cause of CKD                   Total (n = 2,238)   GN (n = 810)    DN (n = 519)    HTN (n = 409)   PKD (n = 364)   *P*
  ------------------------------ ------------------- --------------- --------------- --------------- --------------- -------------------------------------------
  Age (yr)                       53.7 ± 12.2         49.8 ± 12.1     59.3 ± 9.4      59.6 ± 10.8     47 ± 10.6       \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  Sex                                                                                                                
  Male                           1,369 (61.2)        451 (55.7)      357 (68.8)      295 (72.1)      184 (50.5)      \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Female                         869 (38.8)          359 (44.3)      162 (31.2)      114 (27.9)      180 (49.5)      
  Educational attainment                                                                                             
  Illiteracy                     15 (0.8)            6 (0.9)         1 (0.2)         5 (1.4)         2 (0.6)         \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Graduated elementary school    239 (10.8)          56 (8.0)        71 (16.0)       53 (14.7)       19 (5.6)        
  Graduated middle school        259 (11.7)          62 (8.9)        76 (17.2)       41 (11.4)       24 (7.0)        
  Graduated high school          785 (35.3)          268 (38.3)      145 (32.7)      110 (30.6)      98 (28.7)       
  Graduated college or more      906 (40.8)          308 (43.9)      150 (33.8)      151 (42.0)      198 (58.1)      
  Smoking                                                                                                            
  Never smoker                   1,202 (53.9)        478 (59.1)      240 (46.8)      183 (44.9)      228 (62.6)      \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Current smoker                 349 (15.7)          115 (14.2)      84 (16.4)       71 (17.4)       55 (15.1)       
  Former smoker                  677 (30.4)          216 (26.7)      189 (36.8)      154 (37.7)      81 (22.3)       
  Comorbid disease                                                                                                   
  Coronary artery disease        118 (5.3)           14 (1.7)        60 (11.6)       32 (7.8)        2 (0.5)         \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Peripheral vascular disease    78 (3.5)            13 (1.6)        32 (6.2)        20 (4.9)        1 (0.3)         \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Cerebrovascular disease        135 (6.0)           19 (2.3)        51 (9.8)        38 (9.3)        21 (5.8)        \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Diabetes                       755 (33.7)          70 (8.6)        519 (100.0)     72 (17.6)       12 (3.3)        \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Hypertension                   2,150 (96.1)        785 (96.9)      513 (98.8)      407 (99.5)      314 (86.3)      \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Congestive heart failure       34 (1.5)            7 (0.9)         12 (2.3)        10 (2.4)        2 (0.5)         0.025[‡](#t2fn3){ref-type="table-fn"}
  Arrhythmia                     56 (2.5)            18 (2.2)        16 (3.1)        18 (4.4)        2 (0.5)         0.006[†](#t2fn3){ref-type="table-fn"}
  Age-adjusted modified CCI                                                                                          
  Low (≤ 3)                      1,174 (52.5)        627 (77.4)      24 (4.6)        153 (37.4)      317 (87.1)      \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Moderate (4-5)                 652 (29.1)          155 (19.1)      204 (39.3)      193 (47.2)      45 (12.4)       
  High (6-7)                     347 (15.5)          25 (3.1)        242 (46.6)      56 (13.7)       2 (0.5)         
  Very high (8-9)                65 (2.9)            3 (0.4)         49 (9.4)        7 (1.7)         0 (0.0)         
  BMI (kg/m^2^)                  24.6 ± 3.4          24.2 ± 3.3      25.2 ± 3.2      25.1 ± 3.5      23.5 ± 3        \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  BP variables                                                                                                       
  Systolic BP (mmHg)             127.8 ± 16.2        123.4 ± 14.2    134.3 ± 18.5    127.8 ± 15.9    128.3 ± 13.3    \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  Diastolic BP (mmHg)            77 ± 11.1           75.6 ± 10.1     75.7 ± 11.7     77.7 ± 11.5     81 ± 10.4       \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  Pulse pressure (mmHg)          50.8 ± 12.2         47.8 ± 10.6     58.5 ± 13.4     50.1 ± 11.3     47.3 ± 9.8      \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  eGFR (mL/min/1.73 m^2^)        53.1 ± 30.7         60.1 ± 31.4     36.6 ± 21.9     42.3 ± 21.7     72.9 ± 32.9     \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  Urine protein/24 hr (mg/day)   1,353 ± 2,139       1,292 ± 1,524   2,664 ± 3,168   766 ± 1,133     178 ± 256       \< 0.001[\*](#t2fn3){ref-type="table-fn"}
  ACEI or ARB therapy            1,907 (85.4)        726 (89.7)      448 (86.8)      333 (81.6)      285 (78.3)      \< 0.001[†](#t2fn3){ref-type="table-fn"}
  CKD stage                                                                                                          
  Stage G1                       265 (11.8)          131 (16.2)      13 (2.5)        11 (2.7)        94 (25.8)       \< 0.001[†](#t2fn3){ref-type="table-fn"}
  Stage G2                       419 (18.7)          180 (22.2)      44 (8.5)        48 (11.7)       118 (32.4)      
  Stage G3a                      403 (18.0)          163 (20.1)      72 (13.9)       95 (23.2)       52 (14.3)       
  Stage G3b                      484 (21.6)          158 (19.5)      131 (25.2)      112 (27.4)      45 (12.4)       
  Stage G4                       522 (23.3)          138 (17.0)      198 (38.2)      118 (28.9)      42 (11.5)       
  Stage G5 (predialysis)         145 (6.5)           40 (4.9)        61 (11.8)       25 (6.1)        13 (3.6)        

Data are presented as mean ± standard deviation or number (%).

ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCI, Charlson comorbidity index; CKD, chronic kidney disease; DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; G, grade; GN, glomerulonephritis; HTN, hypertensive nephropathy; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; PKD, polycystic kidney disease.

*P* value evaluated by Kruskal-Wallis test; ^†^*P* value evaluated by chi-square test; ^‡^*P* value evaluated by Fisher's exact test.

###### 

Incidences of main outcomes from KNOW-CKD participants as of March 2019

  Outcome events         Event rate per 1,000 person years   *P*                               
  ---------------------- ----------------------------------- ------ ----- ------- ----- ------ ----------
  ESRD                   533                                 57.0   262   98.7    271   40.5   \< 0.001
  ESRD or eGFR halving   662                                 73.8   314   125.1   348   53.9   \< 0.001
  Any CV disease         165                                 16.2   88    28.1    77    10.9   \< 0.001
  Coronary event         76                                  7.4    48    15.3    28    4.0    \< 0.001
  CHF                    9                                   0.9    5     1.6     4     0.6    0.121
  Ischemic stroke        26                                  2.5    17    5.4     9     1.3    \< 0.001
  Cerebral hemorrhage    11                                  1.1    5     1.6     6     0.8    0.295
  Death                  107                                 10.1   62    18.6    45    6.2    \< 0.001

CHF, congestive heart failure; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease.

*P* value from Poisson regression model in the incidence comparisons of diabetes vs. non-diabetes.

###### 

Risk factors for renal composite end-points

              Number of events (%)   Hazard Ratio   95% CI
  ----------- ---------------------- -------------- --------------
  Age                                               
  20-39       81 (25.6)              1              
  40-49       131 (29.7)             0.73           0.55-0.96
  50-59       207 (31.7)             0.52           0.40-0.68
  60-69       182 (32.3)             0.41           0.31-0.54
  ≥ 70        61 (29.6)              0.34           0.24-0.48
  Gender                                            
  Female      266 (31.6)             1              
  Male        396 (29.6)             1.14           0.97-1.33
  DM                                                
  Non-DM      348 (24.0)             1              
  DM          314 (43.1)             1.95           1.66-2.30
  CKD stage                                         
  G1          12 (3.4)               1              
  G2          48 (11.5)              4.10           2.17-7.74
  G3a         66 (18.4)              7.46           4.00-13.89
  G3b         149 (32.4)             14.04          7.72-25.51
  G4          275 (59.5)             41.19          22.85-74.27
  G5          112 (84.8)             145.24         79.12-266.64

Multivariable analysis by Cox proportional hazards model.

CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; G, grade.

###### 

Summary of biomarker discovery studies in KNOW-CKD

  Time frame   Biomarker                    Outcome                              Remarks
  ------------ ---------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  C            Adiponectin                  MS                                   Hypoadiponectinemia is independently associated with the metabolic syndrome in CKD \[[@ref53]\].
  C            Adiponectin                  PEW                                  High serum adiponectin is independently associated with PEW. Among PEW indicators, serum adiponectin is closely associated with urine creatinine excretion as an indirect measure of muscle mass \[[@ref54]\].
  C            Adiponectin                  Albuminuria and renal function       Serum adiponectin is higher in patients with increasing albuminuria, and these levels are associated with albuminuria, renal insufficiency and lipid profiles \[[@ref55]\].
  C            Adiponectin                  hfPWV                                The independent and significant correlation of serum adiponectin concentration with hfPWV in CKD implicates adiponectin in CKD-associated aortic stiffness \[[@ref56]\].
  C, L         Adiponectin                  Anemia                               A high serum adiponectin level is independently associated with a low hemoglobin level and predicts the development of anemia in patients with CKD \[[@ref57]\].
  L            Adiponectin                  Renal event                          Serum adiponectin may be a biomarker of renal dysfunction rather than a true risk factor in CKD progression \[[@ref58]\].
  C            FGF23                        CAC                                  High serum FGF23 was associated with CAC in CKD patients with high adiponectin, but not in those with low adiponectin \[[@ref59]\].
  L            HDL cholesterol              Renal event                          A U-shaped association was observed between serum HDL-C levels and adverse renal outcomes \[[@ref60]\].
  C, L         hs-TnT                       LV structure and function, new LVH   hs-TnT is strongly associated with alterations of LV structure and diastolic dysfunction for both eGFR strata. Baseline hs-TnT levels are predictive of new LVH on follow-up \[[@ref61]\].
  C            Klotho                       LV mass index                        Serum Klotho is an independent biomarker of left ventricular mass index \[[@ref28]\].
  C            Klotho                       MS                                   MS is prevalent in CKD. Serum Klotho is inversely associated with the presence of MS in patients with CKD \[[@ref62]\].
  C            OPG                          baPWV                                Non-traditional, kidney-related cardiovascular risk factors in addition to traditional cardiovascular risk factors are related to serum level of OPG in CKD. Serum OPG level is significantly related to baPWV \[[@ref63]\].
  C            Urine creatinine excretion   PWV                                  24-hour urine creatinine is a marker of muscle mass. Low creatinine excretion is associated with high PWV, suggesting a relationship between decreased muscle mass and arterial stiffness \[[@ref64]\].
  L            Urine Na/K ratio             Renal event                          The Na/K ratio in urine is an index of dietary sodium and potassium intake. The higher Na/K ratio in 24-hour urine collection is associated with higher rate of CKD progression \[[@ref65]\].
  C, L         Urine AGT                    Urinary K excretion, renal event     High urinary AGT level is associated with increased urinary K excretion and renal outcome in patients with PKD \[[@ref66]\].

AGT, angiotensinogen; baPWV, brachial-to-ankle pulse wave velocity; C, cross-sectional; CAC, coronary artery calcification; CKD, chronic kidney disease; FGF23, fibroblast growth factor 23; HDL-C, high density lipoprotein cholesterol; hfPWV, heart-to-femoral pulse wave velocity; hs-TnT, high sensitivity troponin T; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; L, longitudinal; LV, left ventricle; LVH, left ventricular hypertrophy; MS, metabolic syndrome; OPG, osteoprotegerin; PEW, protein-energy wasting; PKD, polycystic kidney disease.

###### 

Basic design and enrollment in Phase I and II of the KNOW-CKD study

  ----------------------------------------------------------------------------------------
  Characteristics                 Phase I          Phase II
  ------------------------------- ---------------- ---------------------------------------
  Timing of enrollment (year)     2011-2016        2019-2021

  Number of participating lefts   9                13

  Number enrolled                 2,238            1,500[a](#t6fn2){ref-type="table-fn"}

  Age (yr)                        20-75            45-79

  CKD Stage or eGFR               CKD G1-G5\       20-60 mL/min/1.73 m^2^
                                  (pre-dialysis)   

  Diabetes                        34%              50%[a](#t6fn2){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------

CKD, chronic kidney disease; eGFR, estimated glomerular filtration; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease.

Planned.

[^1]: Edited by Eun Hui Bae, Chonnam National University, Gwangju, Republic of Korea
